Yaxiang Biomedicine

Ascentage Pharma is a global biopharmaceutical company dedicated to developing novel therapies for cancers, hepatitis B virus (HBV), and age-related diseases. The company leverages its proprietary protein-protein interaction (PPI) drug discovery platform to target the apoptosis pathway, restoring the natural process of programmed cell death in diseased cells. Its lead product, olverembatinib, is a third-generation BCR-ABL inhibitor approved in China for the treatment of drug-resistant chronic myeloid leukemia. Ascentage maintains a robust pipeline of small molecule inhibitors targeting BCL-2, BCL-xL, MDM2-p53, and IAP pathways. Headquartered in Suzhou, China, the company maintains a global footprint with clinical development operations in the United States and is listed on the Hong Kong Stock Exchange.